Press Ganey Acquisition: What It Means for Healthcare GTM

The Press Ganey acquisition by Warburg Pincus in 2023, followed by its merger with Forsta, created one of the most significant data consolidation moves in healthcare experience measurement. For go-to-market teams operating in healthcare, it signals something worth paying attention to: the infrastructure that shapes how providers, payers, and health systems understand patient experience is concentrating, and that concentration has direct implications for how you build market strategy.

This is not a story about one company buying another. It is a story about who controls the data layer that healthcare decisions increasingly rest on, and what that means if your product or service touches the patient experience ecosystem.

Why This Acquisition Matters Beyond the Healthcare Sector

I have spent time working across more than 30 industries, and the pattern is consistent: when the measurement infrastructure of a sector consolidates, the go-to-market playbook for everyone operating in that sector has to change. Press Ganey has long been the dominant player in patient satisfaction benchmarking. Its HCAHPS survey data underpins how hospitals are reimbursed under value-based care models. When that infrastructure gets absorbed into a larger experience data platform through a private equity-backed merger, the implications ripple outward.

For marketers and GTM leaders, the question is not whether this matters. The question is how quickly you can recalibrate your positioning, your sales narrative, and your data strategy to reflect the new landscape your buyers are operating in.

If you want the broader strategic context for how GTM thinking applies across sectors, the work I cover on go-to-market and growth strategy is the right place to start. Healthcare is one of the most structurally complex GTM environments, and the lessons from it travel well.

What Press Ganey Actually Does (and Why It Has Market Power)

Press Ganey collects, benchmarks, and reports on patient experience data across thousands of healthcare organisations. Its surveys feed directly into CMS reimbursement calculations. That is not a soft influence. That is structural leverage over how health systems get paid. Any vendor selling into a hospital system needs to understand that Press Ganey data is not background noise. It is often the primary lens through which clinical and operational leadership evaluates performance.

When Warburg Pincus backed the merger with Forsta, a broader experience management platform, the intent was clear: build a more complete data stack that covers patient experience alongside employee experience and consumer research. From a pure business standpoint, it is a sensible consolidation. From a GTM standpoint, it changes the competitive intelligence environment for everyone selling into health systems.

Forrester has written directly about the structural difficulties of healthcare go-to-market strategy, particularly for device and diagnostics companies. The core tension they identify, that healthcare buyers are simultaneously data-hungry and deeply risk-averse, is the same tension that makes the Press Ganey data ecosystem so powerful. Buyers trust what they already measure. If your product does not connect to the measurement frameworks they rely on, you are starting every conversation at a deficit.

The GTM Implications of Data Consolidation in Healthcare

I ran an agency that grew from 20 to 100 people, and one of the consistent lessons from scaling into new verticals was this: the buyers who seem hardest to reach are usually not hard to reach. They are hard to convince because you have not yet learned to speak in the language of their existing measurement frameworks. Healthcare is the extreme version of that problem.

When Press Ganey consolidates with a broader experience platform, a few things happen simultaneously for GTM teams operating in this space.

First, the benchmarking data that health systems use to evaluate their own performance becomes more integrated. That means a hospital’s leadership team is increasingly looking at patient experience, staff experience, and operational data through a single lens. If your product or service sits at the intersection of any two of those dimensions, you now have a stronger narrative opportunity. But only if you know the data well enough to use it.

Second, the consolidation creates a more defined competitive moat around the incumbents who already have relationships with the Press Ganey platform. Vendors who have built integrations, data partnerships, or case studies tied to Press Ganey metrics will have a structural advantage in sales conversations. Everyone else is playing catch-up.

Third, and this is the one that most GTM teams miss: data consolidation creates blind spots as well as moats. When a dominant measurement platform expands its scope, the risk is that health systems start optimising for what the platform measures rather than what actually matters to patients. That is a market opportunity for any vendor who can demonstrate outcomes that the consolidated platform does not yet capture.

How to Reposition When the Measurement Landscape Shifts

The Vidyard research on why GTM feels harder right now identifies something that maps directly onto the healthcare situation: buyers have more data than ever, but they are less certain about what to do with it. That uncertainty creates a specific kind of sales environment where your job is not to add more data. It is to provide clarity about the data they already have.

For healthcare vendors, that means doing the work to understand exactly how Press Ganey metrics connect to your product’s value proposition. Not in a superficial way. In a way that holds up when a Chief Nursing Officer or a VP of Patient Experience starts asking hard questions.

I have been in enough high-stakes client presentations to know that the moment you lose the room is not when you say something wrong. It is when you say something that reveals you do not fully understand how your buyer’s world works. In healthcare, that world is increasingly organised around the data infrastructure that Press Ganey and its merged entity now controls.

Repositioning in this environment requires three things. You need a clear map of which Press Ganey metrics your product influences, directly or indirectly. You need case studies or reference customers who can speak to that connection in the buyer’s language. And you need a sales narrative that starts with the buyer’s measurement problem, not your product’s feature set.

What Private Equity Involvement Means for the Market

Warburg Pincus is not a passive investor. Private equity involvement in a market-defining data platform means the commercial model will evolve, pricing will likely increase, and the platform will be pushed toward broader adoption to justify the investment thesis. For healthcare organisations, that means the cost of accessing Press Ganey benchmarking data will probably rise over the next few years. For vendors, it means the platform’s commercial footprint will expand, creating both new partnership opportunities and new competitive pressures.

BCG’s work on go-to-market strategy in regulated industries makes the point that market structure changes driven by consolidation tend to reward companies that move early to understand the new landscape. The ones that wait for the dust to settle often find that the structural advantages have already been locked in by faster-moving competitors.

The same logic applies here. If you are selling into health systems and you have not yet mapped your positioning against the merged Press Ganey and Forsta platform, you are behind the curve. Not catastrophically behind, but behind in a market where the sales cycles are long and the switching costs are high.

The Broader Pattern: When Data Platforms Consolidate, GTM Has to Follow

I judged the Effie Awards for several years, which gave me a useful vantage point on how marketing effectiveness is measured and celebrated across industries. One thing that stands out in retrospect is how rarely the winning campaigns were built on proprietary insight. More often, they were built on a sharper reading of publicly available signals that everyone else had access to but most people had not bothered to interpret carefully.

The Press Ganey situation is similar. The information about this acquisition is public. The implications for healthcare GTM are not hidden. But most marketing and sales teams operating in this space have not done the work to translate what happened at the corporate level into a revised go-to-market approach. That gap is where competitive advantage lives, at least for the next 12 to 18 months.

Semrush’s analysis of market penetration strategy is useful here because it frames the challenge correctly: penetrating a market is not primarily about reach or awareness. It is about understanding the decision-making environment well enough to position your offer at the point where it creates the most obvious value. In healthcare, that decision-making environment just changed. The vendors who recognise that will adjust their penetration strategy accordingly.

There is also a talent dimension to this. Healthcare GTM teams that have deep knowledge of patient experience metrics and reimbursement frameworks are now more valuable than they were 18 months ago. If you are building or scaling a team in this space, that expertise needs to be a hiring priority, not an afterthought.

The Risk of Over-Indexing on a Single Data Platform

There is a counterargument worth making here. Any time a single platform gains this much structural influence over how a sector measures performance, there is a risk that the sector starts optimising for the platform rather than for the underlying outcomes the platform is supposed to measure. I have seen this happen in digital marketing more times than I can count. Attribution platforms become the thing teams optimise for, rather than actual business outcomes. The measurement becomes the goal.

In healthcare, the stakes are higher. If health systems start optimising their operations specifically to improve Press Ganey scores rather than to improve actual patient outcomes, that is a problem that extends well beyond marketing strategy. It is a structural distortion of incentives.

For GTM teams, the practical implication is this: do not build your entire value proposition around Press Ganey score improvement if you cannot also demonstrate that your product improves the underlying patient experience that those scores are supposed to reflect. Buyers who are sophisticated enough to ask that question will see through a positioning that optimises for the metric rather than the outcome. And in healthcare, the sophisticated buyers are usually the ones worth winning.

The Vidyard pipeline research on untapped GTM pipeline potential makes a related point: the biggest source of missed revenue is not insufficient reach. It is insufficient clarity about what buyers actually value. In healthcare right now, buyers value data that connects to their existing measurement frameworks, but they are also increasingly aware that those frameworks have limits.

Three Practical Steps for Healthcare GTM Teams Right Now

If you are running or advising a GTM function that operates in or adjacent to the healthcare experience market, here is where to focus your attention.

Map your product’s connection to Press Ganey domains. The platform covers patient experience, workforce engagement, and medical practice surveys. Most healthcare vendors touch at least one of these areas. If you have not explicitly mapped which domains your product influences and how, that work needs to happen before your next sales cycle.

Audit your sales narrative for measurement alignment. Go through your current pitch deck, your case studies, and your website. Count how many times you reference outcomes in the language your buyers use to measure their own performance. If the answer is rarely, you have a positioning gap that is costing you deals.

Identify the blind spots in the consolidated platform. Every measurement system has things it does not capture well. The merged Press Ganey and Forsta platform will have gaps, particularly in areas where patient experience intersects with digital health, remote monitoring, and post-acute care. If your product operates in those spaces, the gap in the dominant measurement framework is your market opportunity.

For more on how to build GTM strategy that holds up in complex, data-heavy buying environments, the go-to-market and growth strategy hub covers the frameworks and thinking I have found most useful across sectors, including healthcare.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions